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. However, different studies 2,3,4,5 suggested olfactory loss in those patients but it remains unclear if it is an early symptom of MS as it is in other neurodegenerative diseases as Parkinson´s disease, Alzheimer´s disease and Huntigton´s disease 6, 7 . The incidence of olfaction in MS is variable. Different trials found an incidence of 15%, 22% and 38.5% when compared to healthy controls 3, 8, 9 . In a recent systematic review of the literature 10 searching for olfactory dysfunction in MS patients, forty articles were analyzed and pointed out a variability in reported frequency, but suggested a prevalence of olfactory dysfunction in 20% to 45% of MS population. The disagreement among investigators may arise from different testing methods, small size of the samples, heterogeneity of the study design but it can also be influenced by corticosteroid treatment as smell function can improve during remission and worsen during relapses.
Although olfactory impaired function in MS and the inability to identify odor were associated to anxiety, depression and to the degree of neurological incapacity 9 , in several studies 11,12,13 , this association was not found when assessing different qualities of olfaction such as the ability to detect odor threshold, the ability to identify and discriminate the odors. Moreover, each quality of olfaction was related to a different phase of the disease. A worse olfactory threshold was observed in the early inflammatory phases while an identification score was more impaired in the widespread chronic disease. This could be explained by smell threshold being part of the more peripheral regions of the olfactory system while the ability to discriminate and identify odors are attributed to several damaged areas of the brain. When analyzing demyelinating plaques in brain MRI of MS patients [2] [3] [4] [5] , the inferior frontal-and temporal-lobe regions, which are involved in olfaction, had a negative relation with smell dysfunction. Considering other brain regions not concerned to olfaction, the number of plaques did not have such relation. Olfactory bulb tract axonal loss was reported in 12 out of 17 MS patients 14 and related to the extension of demyelination in brain, especially in the inferior frontal cortex, although other areas beyond the orbitofrontal cortex are involved in the perception and processing of different odorants, as the insula, cerebellum, visual and cingulate cortex. Therefore, olfactory dysfunction could be an early indication of disease progression, and a marker of widespread disease in the brain.
In this issue of Arquivos de Neuro-Psiquiatria Jordy et al. 15 emphasize olfaction dysfunction as a measure of MS disease activity and progression. In a controlled cross-sectional study they evaluated 100 MS patients using the Connecticut test (CCCRC) to verify the correlation among disease duration, EDSS (Expanded Disability Status Scale) and olfactory dysfunction. They found olfactory dysfunction in 32% of MS patients and this incapacity was more frequent in patients over 38 years old, those with an EDSS above 4.0 and with a longer disease duration. In another robust study 16 , in a sample of 153 MS patients the authors also observed olfactory dysfunction in older MS patients. Although they found 11.1% of MS patients with olfaction identification dysfunction compared to a health control group (3%), this dysfunction was higher in secondary progressive MS (SPMS) (68.8%) than in relapsing-remitting multiple sclerosis (RRMS) (3.3%) also demonstrating the correlation between olfactory dysfunction and longer disease duration. The dynamic changes in olfactory function in the course of MS must be better understood.
In summary, Jordy et al demonstrate that olfaction evaluation in MS patients demands more attention and olfactory dysfunction can be an important tool in the follow-up of MS patients but warrants further research to better understanding of the relationship between olfaction dysfunction and clinical exacerbations. Their results were in accordance with the literature 4,9,11,16 correlating olfactory dysfunction with higher EDSS and longer diagnosis duration. The data gathered could be used in the future to monitor the disease and the response to treatment as in the development of clinical markers to confirm or even predict disease progression in RRMS patients.
